Journal section: Implantology Publication Types: Review

doi:10.4317/medoral.24944

Clinical effect of vitamin C supplementation on bone healing: A systematic review

Kevin Barrios-Garay ¹, Jorge Toledano-Serrabona ², Cosme Gay-Escoda ³, M^a Ángeles Sánchez-Garcés ⁴

¹ DDS. Private practice

² DDS. Fellow of the Master's degree programme in Oral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona. Researcher at IDIBELL (Bellvitge Biomedical Research Institute), Barcelona, Spain

³ MD, DDS, MS, PhD, EBOS, OMFS. Chairman and Professor of Oral and Maxillofacial Surgery, Faculty of Medicine and Health Sciences, University of Barcelona. Director of the Master Degree Program in Oral Surgery and Implantology (EHFRE International University/FUCSO). Coordinator/Researcher at the IDIBELL institute. Head of the Department of Oral Surgery, Implantology and Maxillofacial Surgery, Teknon Medical Center, Barcelona, Spain

⁴ MD, DDS, MS, PhD, EBOS. Lecturer in Oral Surgery. Master's degree program in Oral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona. Researcher at IDIBELL (Bellvitge Biomedical Research Institute), Barcelona, Spain

Correspondence: Facultad de Medicina y Ciencias de la Salud Campus Bellvitge, Universidad de Barcelona C/ Feixa Llarga, s/n; Pavelló Govern 2ª planta, Despacho 2.9 08907 L'Hospitalet de Llobregat; Barcelona, España jorgetoledano25@gmail.com

Received: 20/06/2021 Accepted: 14/02/2022 Barrios-Garay K, Toledano-Serrabona J, Gay-Escoda C, Sánchez-Garcés MÁ. Clinical effect of vitamin C supplementation on bone healing: A systematic review. Med Oral Patol Oral Cir Bucal. 2022 May 1;27 (3):e205-15.



Abstract

Background: The aim of the present systematic review was to evaluate the clinical effect of vitamin C on bone healing after bone fracture or bone reconstruction procedures.

Material and Methods: In October 2020, Cochrane Library, Scopus and PubMed-Medline databases were searched without restrictions to identify animal and human studies that fulfilled the eligibility criteria. Outcome measures were bone healing time, bone gain (mm), bone density and adverse events. The risk of bias assessment of the selected studies was evaluated by means of Cochrane Collaboration's Tool for randomized clinical trials, while randomized clinical animal trials were assessed according to SYRCLE's tool. Additionally, quality of reporting animal studies were assessed according to ARRIVE guidelines.

Results: Out of the 248 articles that yielded the initial search, 11 papers about the effect of ascorbic acid on bone healing were selected. In most of the animal studies, vitamin C seemed to accelerate bone formation owing to an enhanced osteoblastic proliferation and differentiation and its antioxidant function when pro-oxidant substances were added. It was not possible to observe this phenomenon in human studies.

Conclusions: Although additional well-performed animal and human studies are required, vitamin C seems to accelerate bone regeneration without adverse events. However, it is not possible to recommend a specific dose or route of administration of vitamin C to improve the bone healing process in humans as there was great heterogeneity among the included studies.

Key words: Vitamin C, fracture healing, bone regeneration, bone mineral density, implants.

Introduction

Vitamin C (vit C) or ascorbic acid (chemical name: 2,3-didehydro-L-threo-hexane-1,4-lactone) is a watersoluble vitamin obtained from natural or synthetic sources that plays an important role in many biological reactions (1). This vitamin is synthesized from glucose in the liver of most mammalian species, but not in humans or other animal groups (non-human primates, guinea pigs and bats) (2).

An imbalance between the production of reactive oxygen species (free radicals) and antioxidant substances can lead to cell damage and be the cause of various conditions (2). However, vitamin C, as an electron donor, can eliminate hydroxyl and superoxide radicals and, therefore, prevent cell damage by protecting the capillary endothelium and circulating cells (2-4). On the other hand, the importance of vitamin C in bone metabolism is also remarkable, since it is related to the hydroxylation of collagen (5-7), and to the expression of no-collagenic proteins such as alkaline phosphatase, osteonectin and osteocalcin (8). Besides, vit C promotes the expression of genes related to chondrocytes differentiation and is involved in osteoblastogenesis and osteoclastogenesis (4). Indeed, Urban et al. (9) showed that the addition of vit C in concentrations up to 200 µg/ml in cell cultures had a positive effect on osteoblast proliferation and also increased type-I collagen synthesis.

Severe vitamin C deficiency results in scurvy, a disease that is characterized by weakening of collagenous structures, resulting in poor wound healing and impaired immunity (10). Currently, it is difficult to find this condition among the population, however, there are some groups that have a higher requirement of vit C, such as the elderly, alcoholics, smokers and diabetics (10,11). In addition, preclinical and clinical studies have shown that vitamin C deficiency causes a delay in tissue healing and inhibits collagen synthesis (1,12). Furthermore, this deficiency has been linked to an increased risk of osteoporosis and fractures due to decreased bone formation (4).

Bone defects can heal totally or partially depending on local or systemic factors (13,14). When spontaneous bone regeneration is not achieved, additional measures are needed, such as specific surgical techniques and materials (13,15). Several articles have shown that vit C can improve bone healing during regeneration procedures, however, this topic has not yet been systematically reviewed. Thus, a systematic review of animal and human studies investigating the efficacy of the use of vit C as a supplement to a bone healing procedure may add new information.

The purpose of this study was to evaluate the current knowledge on the efficacy of vit C in bone regeneration, as well as to stablish a protocol of dosage and posology of vit C to improve bone healing process.

Material and Methods

The present systematic review was performed according to the statements of "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) (16).

- Eligibility criteria

The focus questions to be addressed were:

How can systemic or oral administration of vit C influence the bone healing process in terms of speed and quality? Are there any differences compare to the bone healing process without Vit C administration? Accordingly, articles that fulfilled the following eligibility criteria were selected (PICO parameters):

(P) Population: Patients or animals treated with vit C.

(I) Intervention: Bone healing using systemic or oral administration of vit C.

(C) Comparison: Bone healing without the use systemic or oral administration of vit C.

(O) Outcomes: For both animal and human studies bone healing time, histomorphometry (bone gain (mm) bone density (HU)) and number of adverse effects were assessed. Additionally, gene/cytokines expression was only assessed in animal studies.

Inclusion criteria were human and animal studies that evaluated the effect of systemically or oral administered vitamin C in terms of bone healing. Studies that evaluated the effect of different vitamins simultaneously were excluded. No restrictions were applied regarding the language and the year of publication.

- Information sources and search strategy

A systematic search in the Cochrane Library, Scopus and PubMed-MEDLINE databases was conducted in October 2020. The following search strategy was used: 1) PubMed-MEDLINE: ("ascorbic acid" [MH] OR "acid, ascorbic" [TIAB] OR "L-ascorbic acid" [TIAB] OR "acid, L-ascorbic" [TIAB] OR "vitamin C" [TIAB]) AND ("bone regeneration" [MH] OR "osteoconduction" [TIAB] OR "bone transplantation" [MH] OR "bone grafting" [TIAB] OR "guided tissue regeneration" [MH] OR "bone remodeling" [MH] OR "fracture healing" [MH] OR "osseointegration" [MH]).

2) Scopus: TITLE-ABS-KEY(("ascorbic acid" OR "vitamin C") AND ("bone regeneration" OR "fracture healing" OR "osseointegration")).

3) Cochrane Library: ("ascorbic acid" OR "vitamin C") AND ("bone regeneration" OR "fracture healing" OR "osseointegration").

Additionally, a cluster search and a manual search of articles published during the last 10 years in "Journal of Clinical Periodontology", "Journal of Periodontal Research", "Clinical Oral investigations", "Journal of Oral and Maxillofacial Surgery" "Medicina Oral Patología Oral y Cirugía Bucal", "Oral Surgery Oral Medicine Oral Pathology Oral Radiology", "Journal of Dentistry", "The International Journal of Oral and Maxillofacial Implants" and "Clinical Oral Implants Research" were carried out. Grey literature was also explored through the Bielefeld Academic Search Engine (BASE).

- Selection process of studies

The selection of the studies was made by two independent reviewers (K.B-G. and J.T-S.). After removing duplicates and screening the remaining articles reading by their title and by their abstract, the studies that fulfilled the eligibility criteria were selected. A third reviewer (M.Á.S-G) with broad experience in systematic reviews resolved any disagreement during the article selection process. Cohen's kappa was calculated to measure the level of agreement between the two reviewers.

- Data collection process and synthesis of the results

A qualitative synthesis was performed using data extraction tables. The following information was retrieved from the selected articles: name of the authors, year of publication, study design, number of participants, description of experimental groups, type of bone defect, vitamin C dosage, exposition route and administration frequency, follow-up time and outcomes variables (healing time, bone gain measured in mm, adverse effects). If necessary, authors of the selected studies were contacted for clarification missing or incomplete data. Since high heterogeneity was found among the selected studies, a quantitative synthesis was not carried out.

- Risk of bias and quality assessment of the included studies

Risk of bias and quality assessment of the included studies was conducted by two independent reviewers (K.B-G and J.T-S). A third reviewer (M.Á.S-G) resolved any disagreements.

Randomized clinical trials (RCT) were evaluated by means of "Cochrane Handbook for Systematic Reviews of Interventions" (17). The following items were classified in low, unclear or high risk of bias: random sequence generation, allocation concealment, patient blinding, outcome blinding, incomplete outcome data and selective reporting. Additionally, the "SYRCLE tool for assessing the risk of bias of animal intervention studies" was used to assess the risk of bias of randomized clinical animal trial (RCAT) studies (18). The following items were classified in low, unclear or high risk of bias: sequence generation, baseline characteristics, allocation concealment, random housing, blinding of the intervention to caregivers and researchers, random outcome assessment, blinding of outcome assessor, incomplete outcome data, selective outcome reporting and other sources of bias. On the other hand, quality of reporting animal studies were assessed according to ARRIVE guidelines (19) for in vivo experiments and assigned predefined grades (study design, sample size, inclusion and exclusion criteria, randomization, blinding, outcome measures, statistical methods, experimental animals, experimental procedures and results). Any disagreement during this step was resolved thanks to one independent investigator (M.Á.S-G).

Results

- Study selection

The initial search yielded 253 studies after eliminating duplicates. After discarding 210 studies by reading their title and 33 by reading the abstract. the full-text of 12 articles was assessed for elegibility (1,11,20-29). Only one study was excluded because evaluated the effect of calcium ascorbate supplemented with vit C metabolites (21). Finally, 11 studies, written in English, were included in the present systematic review; nine animal studies (1,22-29), and two randomized clinical trials (11,20). The level of agreement between the two reviewers was 93.75% with a Cohen's kappa statistic of 0,84.

Fig. 1 shows the flow-chart of the study selection process.

- Risk of bias and quality assessment of the included studies

Regarding animal studies, one study has a high risk of bias and low quality of reporting (22) because it has attrition bias, another has an unclear risk of bias and low quality of reporting (27), other two studies have an unclear risk of bias and an unclear quality of reporting (23,28) and five studies have an unclear risk of bias but high quality of reporting (1,24-26,29) (Fig. 2).

Regarding human studies, both were classified as having high risk of bias. The study of Ekrol *et al.* (11) because it had an attrition bias, whereas the study of Li *et al.* (20) had a high risk of bias due mainly to performance, attrition and reporting bias (Fig. 3).

- Qualitative synthesis

None of the included studies assessed bone gain or bone quality outcomes.



Fig. 1: Flow-chart of the review process following PRISMA statements.

	Random sequence generation	Baseline characteristics	Allocation concealment	Random housing	Blinding of personnel	Random outcome assessment	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting	Other sources of bias
Yilmaz et al. (22)										
Sariszözen et al. (23)										
Duygulu et al. (1)										
Sanbe et al. (24)										
Sanbe et al. (25)										
Uysal et al. (26)										
Giordano et al. (27)										
Choi et al. (28)										
Akça et al. (29)										

Key: Red; high risk of bias, Yellow; unclear risk of bias, Green; low risk of bias

Fig. 2: Assessment of quality and risk of bias of included animal studies.

e208



Fig. 3: The Cochrane collaboration's tool for assessing risk of bias for randomized.

Animal studies

The nine animal studies included comprised 334 rats over a follow-up period ranging from 20 to 98 days. All the studies evaluated the effect of vitamin C in the following clinical scenarios: on bone healing after tibial fracture (22,23,27), on bone defects healing with the addition of pro-oxidant substances (zymosan and nicotine) (1,29), on alveolar bone resorption in rodents fed cholesterol-rich diets (24,25), in bone formation during the expansion of the inter-premaxillary suture (26) and in osteogenic differentiation and osteoclast formation in ovariectomized rats (a useful animal model for evaluating the effect of osteoporotic treatments on the skeletal system) (28) (Table 1).

In Table 2 is depicted the main results of the included animal studies. Two of them (22,23) showed that vit C administration accelerated bone healing after fracture when administered systemically at doses ranging from 0,5 mg/kg to 200 mg/kg. This effect was also observed when pro-oxidant substances were added (1), but a daily dose of 500 mg/kg was necessary. In fact, Akça et al. (29) found that vit C reversed the negative effects produced by nicotine administration on bone healing. In this line, two papers from the same group (24,25) found that vit C diluted in water at concentrations of 1g/l and 2g/l reversed the negative effects on alveolar bone produced by a cholesterol-rich diet (decreased bone density and osteocalcin levels higher expression of hexanoyl-lysine, 8-hydroxideoxyguanosin, nuclear factor kappa beta and RANKL). Conversely, the study by Giordano et al. (27) did not show any benefit from vit C administration at a dose of 200 mg/kg on bone healing after tibial fracture. Regarding the route of administration, Uysal et al. (26) observed that during inter-premaxillary suture expansion, the systemic administration of vit C had significantly better results than local administration of vit C, both at a dose of 0.5 mg/kg. On the other hand, Choi *et al.* (28) observed that oral administration of vit C at doses of 3 mg/kg, 7.5 mg/kg and 15 mg/kg improved bone mineral density and increased the expression of genes involved with osteoblastic differentiation (BMP-2, SMAD 1/5/8, RNTF-2, osteocalcin and COL1) and decreased the expression of genes related to osteoclastic differentiation (RANK, RANKL, TRAP and cathepsin-K) in ovariectomized rats.

Human studies

Regarding the human studies, two randomized clinical trials met the inclusion criteria. These studies comprised 464 patients during a follow-up period ranging from 14 to 365 days (Table 3).

In Table 4 is depicted the main results of the included human studies. Ekrol et al. (11) studied the effect of vit C by oral supplementation at daily dose of 500 mg/ day for 50 days in 336 patients with displaced and nondisplaced distal radial fractures, of whom 87 (25,9%) dropped out within the follow-up period. No statistically differences in, terms of bone healing were observed (11). On the other hand, the study by Li et al. (20) evaluated the effect of oral administration of vit C for 7 days at dose a 300 mg/day after dental implant placement in different clinical scenarios in 128 patients (no patient dropped out). After 14 weeks of follow-up, they observed that vit C improved soft tissue healing (P < 0.05) after dental implant placement in patients who undergoing guided bone regeneration procedures. However, there were no benefits after vit C supplementation in terms of pain management. - Bone healing or implant success were not assessed in the present study.

Since high heterogeneity was found among the selected studies, a quantitative synthesis was not carried out.

Author	Year	Study	Number	Experimental groups	Bone	Dose	Administra-	Fol-
		design	of par-		defect	of vit	tion pathway	low-up
			ticipants			С	and frequency	time
Yilmaz	2001	RCAT	16 Wis-	Group 1: Control (n=8)	Tibial	0,5	Intramuscular	20 days
et al.			tar rats	Group 2 Vit C (n=8)	fracture	mg/kg	(single	
(22)							injection)	
Sa-	2002	RCAT	48	Group 1: Vit E (n=12)	Tibial	200	Intraperitoneal	21 days
riszözen			Sprague-	Group 2: Vit C (n=12)	fracture	mg/kg	(every day for	
et al.			Dawley	Group 3: Vit C + E 40 (n=12)			3 days before	
(23)			rats	Group 4: Control (n=12)			fracture and	
							3 days every	
							week after	
							fracture)	
Duygulu	2007	RCAT	50	Group 1: Control (saline) (n=10)	Ulna	500	Intraperitoneal	21 days
<i>et al.</i> (1)			Wistar	Group 2: Zymosan (n=10)	and	mg/kg	(daily)	
			rats	Group 3: Zymosan + DMSO (n=10)	radius			
				Group 4: Zymosan + EGb.761 (n=10)	fracture			
~ 1				Group 5: Zymosan + vit C (5 n=10)				
Sanbe <i>et</i>	2007	RCAT	24	Group 1: Control (n=6)	Alveo-	1 g/l	Oral (diluted	84 days
al. (24)			Wistar	Group 2: High rich cholesterol diet (n=6)	lar bone	2 g/1	in still water)	
			rats	Group 3: High rich cholesterol diet + vit C	resorp-		(dally)	
				(n=6)	tion			
				Group 4: High fich choiesterol diet + VII C $(n=6)$				
Sanha at	2000	PCAT	24	(1-0) Group 1: Control (n=6)	Alveo	$1 \alpha/1$	Oral (diluted	84 days
al (25)	2009	KCAI	Wistar	Group 2: High rich cholesterol diet $l(n=6)$	lar hone	$\frac{1}{2} \frac{g}{a}$	in still water)	04 uays
<i>ui.</i> (23)			rats	Group 3: High rich cholesterol diet $1 + vit$	resorn-	2 5/1	(daily)	
			1415	C (n=6)	tion		(dully)	
				Group 4 [•] High rich cholesterol diet + vit C	tion			
				(n=6)				
Uysal et	2011	RCAT	30	Group 1: Control (inter-premaxillary suture	NR	0,5 mg	Local injection	20 days
al. (26)			Wistar	expansion + saline) $(n=10)$		/kg	(inter-premaxil-	-
			rats	Group 2: Inter-premaxillary suture expan-		-	lary suture)	
				sion + local vit C (n=10)			Intramuscular	
				Group 3: Inter-premaxillary suture expan-			Intramuscular	
				sion + systemic vit C (n=10)			(single injec-	
		ļ					tion)	
Gior-	2012	RCAT	30	Group A: Vit C (n=15)	Tibial	200	Intraperitoneal	36 days
dano <i>et</i>			Wistar	Group B: Control (n=15)	fracture	mg/kg	(daily)	
al.(27)	2010	DOAT	rats		ND			00.1
Choi et	2019	RCAI	60 Winter	Group 1: Sham control (sham-operated) $(n-10)$	NK	3 mg/	Gavage (daily)	98 days
al. (28)			wistar	(n=10)		kg		
			Tais	C_{10} C		$\frac{1.3}{ma/ka}$		
				Group 3: Positive control (ovariectomy +		11 g/kg		
				normal diet) (n=10)		kg		
				Group 4: Ovariectomy + vit C (n=10)				
				Group 5: Ovariectomy + vit C ($n=10$)				
				Group 6: Ovariectomy + vit C (n=10)				
Akça et	2020	RCAT	52	Group 1*: Control (n=10)	Surgi-	200	Intraperitoneal	21 days
al. (29)			Sprague-	Group 2*: Vit C (n=14)	cally	mg/kg	(every day for	
			Dawley	Group 3*: Nicotine(n=14)	induced		the first 3 days	
			rats	Group 4*: Nicotine + vit C (n=14)	tibial		and then every	
				*Each group contained 2 subgroups sacri-	defect.		other day post-	
				ficed after 7 and 21 days			operatively)	

Abbreviations: RCAT; Randomized controlled animal trial, Vit; vitamin, DMSO: dimethyl sulfoxide, EGb.761; Ginkgo biloba extract, NR; Not reported.

Author	Bone healing time	Bone density	Additional data
Yilmaz et	On the 15th day the vit C group showed	NR	NR
al. (22)	callus formation with small osteoid tissue		
()	clusters while the control group had		
	granulation tissue and chondroid cells		
Sariszözen	In the vit C group on 21st day the mean cal-	NR	NR
et al (23)	lus indices and histological assessment of		
<i>ci ui</i> . (25)	bone union were higher than control group		
Duvgulu <i>et</i>	Zymosan inhibited the fracture healing	NR	NR
al (1)	The simultaneous administration of vit C		
un. (1)	prevented this effect. No differences were		
	found com-paring this simultaneous ad-		
	ministration of vit C to the control group		
	on the 22nd day		
Sanbe <i>et al</i>	NB	Alveolar bone den-	High rich cholesterol diet decreased osteocalcin
(24)		sity was reduced	levels and increased serum levels of 8-OHdg
(21)		by a rich choles-	The groups with vit C intake reduced these
		terol diet Vit C	negative effects
		prevented this neg-	
		ative effect and im-	
		proved bone densi-	
		ty compared to the	
		control group	
Sanbe <i>et al.</i>	NR	NR	There were incremented serum levels of HEL
(25)			and TRAP-positive osteoclasts with an increase
(-)			in NF-kß (RANK) and RANKL expression by
			a high rich cholesterol diet. The groups with vit
			C intake reduced these negative effects
Uysal <i>et al</i> .	NR	NR	Systemically administered vit C improved the
(26)			inter-premaxillary suture bone formation. Lo-
× ,			cal vit C administration worsened bone forma-
			tion compared to the control group
Giordano	No differences between groups at 6 weeks.	NR	NR
<i>et al.</i> (27)	Both groups had histological complete		
. ,	bone union		
Choi <i>et al</i> .	NR	NR	A higher number of osteoblasts, osteoclasts and
(28)			osteocytes was observed histologically. Gene
< <i>/</i>			expression of genes related to osteoblastic dif-
			ferentiation was incremented (BMP-2, SMAD
			1/5/8, RNX2, osteocalcin and type-I collagen).
			A decrease of gene expression of genes related
			to osteoclastic differentiation (NF- kb, TRAP
			and cathepsin-K). Vit C prevented osteoporosis
			promoting osteoblastic formation and inhibit-
			ing osteoclastogenesis through Wnt/β-Catenin/
			ATF4 and MAPK signaling pathways
Akça et al.	The groups with vit C administration did	NR	Nicotine incremented VEGF, HIF-1 α and
(29)	not show differences compared to the		BMP-2 expression but the group with simul-
	control group on the 21st day		taneous administration of vit C did not show
			significant changes in expression levels. Thus,
			Vit C prevented the negative effect produced by
			nicotine administration

 Table 2: Outcomes of the included animal studies.

Abbreviations: Vit; vitamin, NR; Not reported. 8-OHdG; 8-hydroxydeoxyguanosine, HEL; hexanoyl-lysine, TRAP; tartrateresistant acid phosphatase, NF-kβ; nuclear factor kappa beta (RANK), RANKL; nuclear factor kappa beta ligand, BMP; bone morphogenetic protein; MAPK; Mitogen-activated protein kinase VEGF: Vascular endothelial growth factor, HIF-1α; hypoxiainducible factor 1-alpha.

Au-	Year	Study	Number	Experimental groups	Bone	Dosage	Administra-	Follow-
thor		design	of partici-		defect		tion pathway	up time
			pants				and frequency	(days)
Ekrol	2014	RCT	336	Group 1: vit C (n=124)	Distal	500 mg	Oral (daily	365 days
et al.			adults (87	Subgroup 1: Displaced fracture + vit C	radial		during 50 days	
(11)			dropouts -	(n=70)	fracture		after interven-	
			25.9%)	Subgroup 2: Non-displaced fracture +			tion)	
				vit C (n=54)				
				Grupo 2: placebo (n=125)				
				Subgroup 1: displaced fracture + pla-				
				cebo (n=68)				
				Subgroup 2: non-displaced fracture +				
			ļ	placebo (n=57)				
Li et al.	2018	RCT	128 adults	Group A: implant placement + GBR	Implant	300 mg	Oral (daily	14 days
(20)			(0 dropouts	(xenograft covered using a collagen	place-		during 7	
			- 0%)	membrane) (n=30)	ment		days after	
				Subgroup 1: + vit C (n=15)			intervention)	
				Subgroup 2: control (n=15)				
				Grupo B: Implant placement + xeno-				
				graft (n=30)				
				Subgroup 1: + vit C (n=15)				
				Subgroup 2: control (n=15)				
				Grupo C: implant placement in patients				
				with chronic periodontitis (n=32)				
				Subgroup 1: + vit C (n=17)				
				Subgroup 2: control (n=15)				
				Group D: Implant placement in peri-				
				odontitis free patients (n=36)				
				Subgroup 1: + vit C (n=18)				
	1			Subgroup 2: control (n=18)				

Table 3: Description of the included human studies

Abbreviations RCT; randomized clinical trial, Vit; vitamin, GBR; guided bone regeneration, NR: not reported

Table 4: Outcomes of the included human studies.

Author	Bone healing time	Bone	Bone	Adverse events	Additional results
		gain	density		
Ekrol <i>et al.</i> (11)	No statistically sig- nificant differences in fracture healing were observed due to vit C administration (p=0.42 and 0.23)	NR	NR	At 26 weeks the vit C sup- plemented group showed a higher rate of complica- tions ($p=0.043$) and pain in the group with displaced fractures ($p=0.045$)	No statistically significant differences in DASH score nor CRPS at 52 weeks owing to vit C administration com- pared to the control groups
Li <i>et al.</i> (20)	NR	NR	NR	NR	Vit C administration improved wound healing indices after intervention af- ter 14 days in all groups except in the group with periodontitis free patients. Vit C administration did not improve postoperative pain management

Abbreviations: NR; Not reported, Vit; vitamin, DASH; Disabilities of the arm, shoulder and hand, CRPS: Complex regional pain syndrome.

Discussion

According to the results of the included animal studies, the administration of vit C seems to improve bone healing and bone formation, as vit C may modulate osteoblastogenesis and osteoclastogenesis, and also has an antioxidant function. However, data extracted from the included RCTs did not show any additional benefits of oral vit C supplementation on either bone healing or bone regeneration.

Different results were found regarding bone healing speed among the included animal studies. This fact could be due to the ability of rodents to synthesize vit C from a normal diet (30). This makes it necessary to know exactly the dietary pattern of the animals. Thus, whereas the rodents in the study by Giordano *et al.* (27) had unlimited access to food, the feeding pattern followed in the studies by Yilmaz *et al.* (22) and Sariszözen *et al.* (23) was not exactly explained.

Uysal *et al.* (26) described that locally injected vit C had a negative impact on bone formation after expanding the inter-premaxillary suture. The authors explained that this could be due to an alteration in apoptotic regulation related to bone healing (26). However, the lack of further studies evaluating the local effect of vit C makes it impossible to know if this is an isolated phenomenon or if it is really due to this route of administration. Nevertheless, the authors observed that systemic administration of vit C obtained good results in terms histomorphometry of bone formation (26).

A minimum intake of 75 mg/day for adult women and 90 mg/day for adult men of vit C has been recommended in The United States of America and Canada (4). Additionally, an increase of this intake values is recommended in 15 mg/day for pregnant women, 50 mg/day if lactating, and 35 mg/day for smokers (4).

Smokers are constantly exposed to a source of prooxidant substances and reactive oxygen species that lead to an increased requirement of vit C (3). However, taking into account that nicotine also has a negative effect on osteoblastic proliferation (31) and that the vit C requirement is higher in smokers (2,4), we believe that vit C supplementation should be indicated in these patients, especially when they undergo bone regeneration procedures of the jaws or after traumatic injuries. In our review, two studies (1,29) induced the formation of free radicals and reactive oxygen species by administration of zymosan and nicotine. The authors observed that vit C acts as an antioxidant by scavenging these free radicals (1-3), which explains the good bone healing reported in these studies. In this line, Tomofujiet al. (32) evaluated Wistar rats fed a cholesterol-rich diet and demonstrated that this type of diet can initiate and increase bone loss around the teeth. However, it seems that, as demonstrated in the studies of Sanbeet al. (24,25), vit C prevents the negative effects produced by this type of diet. This is mainly due to the inhibition of lipid peroxidation and an increase in osteoblastic proliferation and differentiation genes, as well as a decrease in osteoclastic prolifer- ation and differentiation genes. Regarding human studies, Ekrol et al. (11) did not observe an improved bone healing due to vit C administration, however, they pointed out that the benefits of vit C administration may only be observable in vit C-deficient populations On the other hand, Li et al. (20) suggested that vit C improves surgical wound healing after dental implant placement, but the study did not evaluate the effect of vit C on bone regeneration by radiography or histology.

The scientific literature describes some adverse effects associated with vit C supplementation, such as diarrhea and abdominal pain, with high dose in a single administration. Hyperuricosuria has been described in vit C concentrations higher than 3 g, hyperoxaluria in concentrations higher than 1 g, hyperoxalemia in patients treated with hemodialysis when administered intravenously repeatedly in doses of 1 g and hemolysis in patients with phosphate-6-glucose dehydrogenase deficiency administered intravenously or orally when the concentration is higher than 6 g in a single dose (33). In our review, none of the selected studies reported any of the adverse events mentioned above.

Regarding the use of other vitamins to aid bone formation and healing, vitamins D and E have also been studied. Carinci et al. (34) studied vitamins C and E to evaluate their effect on preosteoblast gene expression. Vitamin E showed no effect, whereas vitamin C modified preosteoblast genes by increasing cell growth, metabolism, morphogenesis and cell communication. Similarly, one of the studies included in this review used vit E on bone healing (23), and showed no additional benefit, not even associated with vit C. On the other hand, the use of vit D supplementation can be useful in patients with osteoporosis as vit D has a crucial role on bone mineralization. In fact, vit D deficit has been associated to a worse dental implant osteointegration and an increased risk of early implant failure (35). However, as with vit C, further studies are still required to confirm the clinical effect of their oral supplementation.

Finally, there are several limitations related to the present systematic review that should be mentioned. First, most of the included studies were animal studies which may represent a problem in the external validation of their results. Furthermore, only two RCTs with low quality related to vit C administration could be included. Another limitation was the heterogeneity found among the selected articles, which prevents us from comparing the results obtained with respect to bone defect, different bone regeneration techniques and populations with higher vit C requirements (elderly, diabetics and smokers). To overcome these limitations, it is necessary to perform well-designed RCTs to determine whether vit C supplementation in standardized models of bone defects implies any benefit in the speed of healing or in the quality of bone obtained in patients without dietary vit C deficiency. An experimental animal model with a cranial bone defect of critical size could be useful to compare various groups (test and control), in terms of histomorphometry, at different time points and vitamin C doses. The defect proposed by Higuchy et al. (36) or by Kustro et al.(37) or especially by Liu et al. (38) because of its dimension, will help to confirm the null hypothesis of the present work.

There is enough evidence that vitamin C has good re-

sults at the in vitro level regarding osteoblast differentiation and maturation and, it is possible to think that it could be a very easy way to improve bone and soft tissue healing conditions, without increasing morbidity and cost of a treatment.

Bone tissue regeneration and dental implant placement are increasing, especially among elderly patients. If our hypothesis is confirmed, recommending vit C supplementation during the bone healing period could be an effective, inexpensive and easy-to-implement treatment. These supplements could be especially useful in smoking patients, and hypercholesterolemic patients due to the requirement of antioxidants.

The techniques used in oral and implant surgery are constantly improving using different materials, some of them experimental or expensive, and it seems that there is no room for simplicity and, in certain cases, less could be more.

Conclusions

Although additional well-performed animal and human studies are required, vitamin C seems to accelerate bone regeneration without adverse events. However, it is not possible to recommend a specific dose or route of administration of vitamin C to improve the bone healing process in humans as there was great heterogeneity among the included studies.

References

1. Aghajanian P, Hall S, Wongworawat M, Mohan S. The roles and mechanisms of actions of vitamin C in bone: New developments. J Bone Miner Res. 2015;30:1945-55.

2. Duygulu F, Yakan B, Karaoglu S, Kutlubay R, Karahan OI, Ozturk A. The effect of zymosan and the protective effect of various antioxidants on fracture healing in rats. Arch Orthop Trauma Surg. 2007;127:493-501.

3. Kim SH, Kim JS, Shin HS, Keen CL. Influence of smoking on markers of oxidative stress and serum mineral concentrations in teenage girls in Korea. Nutrition. 2003;19:240-3.

4. Buettner GR. The pecking order of free radicals and antioxidants: Lipid peroxidation, α -yocopherol, and ascorbate. Arch Biochem Biophys. 1993;300:535-43.

5. Schwarz RI. Procollagen secretion meets the minimum requirements for the rate-controlling step in the ascorbate induction of procollagen synthesis. J Biol Chem. 1985;260:3045-9.

6. Vuorela A, Myllyharju J, Nissi R, Pihlajaniemi T, Kivirikko KI. Assembly of human prolyl 4-hydroxylase and type III collagen in the yeast Pichia pastoris: Formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase. EMBO J. 1997;16:6702-12.

7. Marini JC, Cabral WA, Barnes AM, Chang W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell Cycle. 2007;6:1675-81.

8. Franceschi RT, Iyer BS. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J Bone Miner Res. 1992;7:235-46.

9. Urban K, Höhling HJ, Lüttenberg B, Szuwart T, Plate U. An in vitro study of osteoblast vitality influenced by the vitamins C and E. Head Face Med. 2012;8:1-10.

10. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9:1-25.

11. Ekrol I, Duckworth AD, Ralston SH, Court-Brown CM, Mc-Queen MM. The influence of vitamin C on the outcome of distal radial fractures. J Bone Joint Surg Am. 2014;96:1451-9.

12. Moores J. Vitamin C: A wound healing perspective. Br J Community Nurs. 2013;S6:S8-11.

 Benic GI, Hämmerle CHF. Horizontal bone augmentation by means of guided bone regeneration. Periodontol 2000. 2014;66:13-40.
 Donos N, Dereka X, Mardas N. Experimental models for guided bone regeneration in healthy and medically compromised conditions. Periodontol 2000. 2015;68:99-121.

15. Thrivikraman G, Athirasala A, Twohig C, Boda K, Bertassoni L. Biomaterials for craniofacial bone Regeneration. Dent Clin North Am. 2018;61:1835-56.

16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA 2020 statement: An updated guide-line for reporting systematic reviews. PLoS Med. 2021;18:e1003583.

17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.

18. Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:1-9.

19. du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, *et al.* The arrive guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:1-12.

20. Li X, Tang L, Lin YF, Xie GF. Role of vitamin C in wound healing after dental implant surgery in patients treated with bone grafts and patients with chronic periodontitis. Clin Implant Dent Relat Res. 2018;20:793-8.

21. Rowe DJ, Ko S, Tom XM, Silverstein SJ, Richards DW. Enhanced production of mineralized nodules and collagenous proteins in vitro by calcium ascorbate supplemented with vitamin C metabolites. J Periodontol. 1999;70:992-9.

22. Yilmaz C, Erdemli E, Selek H, Kinik H, Arikan M, Erdemli B. The contribution of vitamin C to healing of experimental fractures. Arch Orthop Trauma Surg. 2001;121:426-8.

23. Sarisözen B, Durak K, Dinçer G, Bilgen OF. The effects of vitamins E and C on fracture healing in rats. J Int Med Res. 2002;30:309-13.

24. Sanbe T, Tomofuji T, Ekuni D, Azuma T, Tamaki N, Yamamoto T. Oral administration of vitamin C prevents alveolar bone resorption induced by high dietary cholesterol in rats. J Periodontol. 2007;78:2165-70.

25. Sanbe T, Tomofuji T, Ekuni D, Azuma T, Irie K, Tamaki N, *et al.* Vitamin C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high-cholesterol diet. Arch Oral Biol. 2009;54:235-40.

26. Uysal T, Amasyali M, Olmez H, Enhos S, Karslioglu Y, Gunhan O. Effect of vitamin C on bone formation in the expanded inter-premaxillary suture. Early bone changes. J Orofac Orthop. 2011;72:290-300.

27. Giordano V, Albuquerque RP, do Amaral NP, Chame CC, de Souza F, Apfel MIR. Supplementary vitamin C does not accelerate bone healing in a rat tibia fracture model. Acta Ortop Bras. 2012;20:10-2. 28. Choi HK, Kim G-J, Yoo H-S, Song DH, Chung K-H, Lee K-J, *et al.* Vitamin C activates osteoblastogenesis and inhibits osteoclastogenesis via Wnt/β-catenin/ATF4 signaling pathways. Nutrients. 2019;11:1-20.

 Akça EK, Atalay B, Öner B. Histopathologic and immunohistochemical investigation of the effects of vitamin C on bone healing in rats exposed to nicotine. J Oral Maxillofac Surg. 2020;78:194.e1-14.
 Gabbay KH, Bohren KM, Morello R, Bertin T, Liu J, Vogel P. Ascorbate synthesis pathway: Dual role of ascorbate in bone homeostasis. J Biol Chem. 2010;285:19510-20.

31. Kim HH, Lee SE, Chung WJ, Choi Y, Kwack K, Kim SW, *et al.* Stabilization of hypoxia-inducible factor- 1α is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine. 2002;17:14-27.

32. Tomofuji T, Kusano H, Azuma T, Ekuni D, Yamamoto T, Watanabe T. Effects of a high-cholesterol diet on cell behavior in rat periodontitis. Practitioner. 2005;249:752-6.

33. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. J Am Med Assoc. 1999;281:1415-23.

34. Carinci F, Pezzetti F, Spina AM, Palmieri A, Laino G, De Rosa A, *et al.* Effect of vitamin C on pre-osteoblast gene expression. Arch Oral Biol. 2005;50:481-96.

35. Nastri L, Moretti A, Migliaccio S, Paoletta M, Annunziata M, Liguori S, *et al*. Do dietary supplements and nutraceuticals have effects on dental implant osseointegration? A scoping review. Nutrients. 2020;12:268.

36. Higuchi T, Kinoshita A, Takahashi K, Oda S, Ishikawa I. Bone Regeneration by Recombinant Human Bone Morphogenetic Protein-2 in Rat Mandibular Defects. An Experimental Model of Defect Filling. J Periodontol. 1999;70:1026-31.

37. Kustro T, Kiss T, Chernohorskyi D, Chepurnyi Y, Helyes Z, Kopchak A. Quantification of the mandibular defect healing by micro-CT morphometric analysis in rats. J Cranio-Maxillofacial Surg. 2018;46:2203-13.

38. Liu G, Guo Y, Zhang L, Wang X, Liu R, Huang P, *et al.* A standardized rat burr hole defect model to study maxillofacial bone regeneration. Acta Biomater. 2019;86:450-64.

Acknowledgements

This study was carried out by the research group "Odontologic and Maxillofacial Pathology and Therapeutics" of the Biomedical Investigation Institute of Bellvitge (IDIBELL).

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Conflict of interest

The authors declare that they do not have any conflict of interest.

Authors contributions

Kevin Barrios-Garay and Jorge Toledano-Serrabona: Acquisition, analysis and interpretation of the data, drafting of the article; approval of the final version of the manuscript and agreement to be accountable for all aspects of the work.

Cosme Gay-Escoda: Drafting of the article; critical review of the manuscript; approval of the final version of the manuscript and agreement to be accountable for all aspects of the work.

M^a Ángeles Sánchez-Garcés: Conception and design of the study; interpretation of the data; drafting of the article; approval of the final version of the manuscript and agreement to be accountable for all aspects of the work.